<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
 <result pre="This strategy can be crucial for the first-line treatment of" exact="acute" post="infections or coinfections and for the management of drug-resistant"/>
 <result pre="strategy can be crucial for the first-line treatment of acute" exact="infections" post="or coinfections and for the management of drug-resistant strains."/>
 <result pre="virus names AdV Adenovirus CHIKV Chikungunya virus CMV Cytomegalovirus DENV" exact="Dengue" post="virus EBOV Ebola virus EBV Epstein–Barr virus FLUAV Influenzavirus"/>
 <result pre="EBOV Ebola virus EBV Epstein–Barr virus FLUAV Influenzavirus A HBV" exact="Hepatitis" post="B virus HCV Hepatitis C virus HIV Human immunodeficiency"/>
 <result pre="Epstein–Barr virus FLUAV Influenzavirus A HBV Hepatitis B virus HCV" exact="Hepatitis" post="C virus HIV Human immunodeficiency viruses HMPV Human metapneumovirus"/>
 <result pre="HBV Hepatitis B virus HCV Hepatitis C virus HIV Human" exact="immunodeficiency" post="viruses HMPV Human metapneumovirus HSV Herpes simplex virus MARV"/>
 <result pre="simplex virus MARV Marburg virus RSV Human orthopneumovirus MulV Murine" exact="leukaemia" post="virus RVFV Rift Valley fever virus SINV Sindbis virus"/>
 <result pre="Marburg virus RSV Human orthopneumovirus MulV Murine leukaemia virus RVFV" exact="Rift Valley fever" post="virus SINV Sindbis virus VZV Varicella zoster virus YFV"/>
 <result pre="virus RVFV Rift Valley fever virus SINV Sindbis virus VZV" exact="Varicella" post="zoster virus YFV Yellow fever virus ZIKV Zika virus"/>
 <result pre="RVFV Rift Valley fever virus SINV Sindbis virus VZV Varicella" exact="zoster" post="virus YFV Yellow fever virus ZIKV Zika virus 1"/>
 <result pre="fever virus SINV Sindbis virus VZV Varicella zoster virus YFV" exact="Yellow fever" post="virus ZIKV Zika virus 1 Introduction Epidemics and pandemics"/>
 <result pre="Health Organization (WHO) has been issuing a report on new" exact="viral" post="pathogens that pose a threat to public health almost"/>
 <result pre="or by strains that are more pathogenic than the preceding" exact="viral" post="pathogens necessitate the development of effective strategies for combating"/>
 <result pre="necessitate the development of effective strategies for combating and preventing" exact="viral" post="infections. Immunoprophylaxis by a specific vaccination is one of"/>
 <result pre="is one of the most important strategies for combating many" exact="infectious diseases." post="However, there are still many viruses for which no"/>
 <result pre="antiviral drugs is the only possible way to fight against" exact="infections" post="caused by viruses. The introduction of new antiviral agents"/>
 <result pre="agents for clinical use has revolutionized the treatment of many" exact="viral" post="infections caused by either DNA or RNA viruses (De"/>
 <result pre="for clinical use has revolutionized the treatment of many viral" exact="infections" post="caused by either DNA or RNA viruses (De Clercq"/>
 <result pre="the approved drugs have been licensed for the treatment of" exact="infections" post="caused by a single virus. However, some drugs with"/>
 <result pre="drugs and their acyclic analogues that exhibit multi-target activity against" exact="viral" post="infections of great medical importance (e.g., herpes simplex virus"/>
 <result pre="and their acyclic analogues that exhibit multi-target activity against viral" exact="infections" post="of great medical importance (e.g., herpes simplex virus (HSV),"/>
 <result pre="multi-target activity against viral infections of great medical importance (e.g.," exact="herpes" post="simplex virus (HSV), varicella zoster virus (VZV), human immunodeficiency"/>
 <result pre="infections of great medical importance (e.g., herpes simplex virus (HSV)," exact="varicella" post="zoster virus (VZV), human immunodeficiency virus (HIV), hepatitis B"/>
 <result pre="of great medical importance (e.g., herpes simplex virus (HSV), varicella" exact="zoster" post="virus (VZV), human immunodeficiency virus (HIV), hepatitis B virus"/>
 <result pre="(e.g., herpes simplex virus (HSV), varicella zoster virus (VZV), human" exact="immunodeficiency" post="virus (HIV), hepatitis B virus (HBV) and hepatitis C"/>
 <result pre="virus (HSV), varicella zoster virus (VZV), human immunodeficiency virus (HIV)," exact="hepatitis" post="B virus (HBV) and hepatitis C virus (HCV)) and/or"/>
 <result pre="(VZV), human immunodeficiency virus (HIV), hepatitis B virus (HBV) and" exact="hepatitis" post="C virus (HCV)) and/or that are known antineoplastic agents"/>
 <result pre="developmenta Experimental development Acyclovir Acyclic guanosine analogue HSV, VZV (1982)" exact="Breast cancer" post="(Shaimerdenova et al., 2017)EBV (Pagano et al., 2018) Azacitidine"/>
 <result pre="Experimental development Acyclovir Acyclic guanosine analogue HSV, VZV (1982) Breast" exact="cancer" post="(Shaimerdenova et al., 2017)EBV (Pagano et al., 2018) Azacitidine"/>
 <result pre="et al., 2017)EBV (Pagano et al., 2018) Azacitidine Cytidine analogue" exact="Myelodysplastic syndrome" post="(2004) AdV (Alexeeva et al. (2001); (Alexeeva et al.,"/>
 <result pre="al., 2017)EBV (Pagano et al., 2018) Azacitidine Cytidine analogue Myelodysplastic" exact="syndrome" post="(2004) AdV (Alexeeva et al. (2001); (Alexeeva et al.,"/>
 <result pre="2018) Brivudine Thymidine analogue HSV-1, VZV (2002)b Clofarabine Adenosine analogue" exact="Acute" post="lymphoblastic leukaemia (2004) HIV-1 (Daly et al., 2016)HIV-1, HIV-2"/>
 <result pre="Thymidine analogue HSV-1, VZV (2002)b Clofarabine Adenosine analogue Acute lymphoblastic" exact="leukaemia" post="(2004) HIV-1 (Daly et al., 2016)HIV-1, HIV-2 (Beach et"/>
 <result pre="al., 2016)HIV-1, HIV-2 (Beach et al., 2014) Decitabine Cytidine analogue" exact="Myelodysplastic syndrome" post="(2006) HIV-1 (Clouser et al., 2010)HIV-1 – synergy in"/>
 <result pre="2016)HIV-1, HIV-2 (Beach et al., 2014) Decitabine Cytidine analogue Myelodysplastic" exact="syndrome" post="(2006) HIV-1 (Clouser et al., 2010)HIV-1 – synergy in"/>
 <result pre="al., 2018) Gemcitabine Cytidine analogue Various carcinomas (1995): non-small cell" exact="lung cancer," post="pancreatic cancer, bladder cancer breast cancer ovarian cancer HIV-1"/>
 <result pre="Gemcitabine Cytidine analogue Various carcinomas (1995): non-small cell lung cancer," exact="pancreatic cancer," post="bladder cancer breast cancer ovarian cancer HIV-1 (Rawson et"/>
 <result pre="analogue Various carcinomas (1995): non-small cell lung cancer, pancreatic cancer," exact="bladder cancer" post="breast cancer ovarian cancer HIV-1 (Rawson et al. (2013);"/>
 <result pre="Various carcinomas (1995): non-small cell lung cancer, pancreatic cancer, bladder" exact="cancer" post="breast cancer ovarian cancer HIV-1 (Rawson et al. (2013);"/>
 <result pre="carcinomas (1995): non-small cell lung cancer, pancreatic cancer, bladder cancer" exact="breast cancer" post="ovarian cancer HIV-1 (Rawson et al. (2013); Clouser et"/>
 <result pre="(1995): non-small cell lung cancer, pancreatic cancer, bladder cancer breast" exact="cancer" post="ovarian cancer HIV-1 (Rawson et al. (2013); Clouser et"/>
 <result pre="non-small cell lung cancer, pancreatic cancer, bladder cancer breast cancer" exact="ovarian cancer" post="HIV-1 (Rawson et al. (2013); Clouser et al. (2010);"/>
 <result pre="cell lung cancer, pancreatic cancer, bladder cancer breast cancer ovarian" exact="cancer" post="HIV-1 (Rawson et al. (2013); Clouser et al. (2010);"/>
 <result pre="analogue HSV, VZV (1996) Ribavirin Nucleoside analogue RSV, HCV (1985)" exact="viral" post="haemorrhagic fevers HBV (phase 3, (NCT03759782, in combination with"/>
 <result pre="in combination with inarigivir) Trifluridine Thymidine analogue HSV (1980) Metastatic" exact="colorectal cancer" post="(2015) in combination with tipiracil Mycoplasma pneumonia (Sun and"/>
 <result pre="combination with inarigivir) Trifluridine Thymidine analogue HSV (1980) Metastatic colorectal" exact="cancer" post="(2015) in combination with tipiracil Mycoplasma pneumonia (Sun and"/>
 <result pre="HSV (1980) Metastatic colorectal cancer (2015) in combination with tipiracil" exact="Mycoplasma pneumonia" post="(Sun and Wang, 2013) Valaciclovir Acyclic guanosine analogue HSV,"/>
 <result pre="(1980) Metastatic colorectal cancer (2015) in combination with tipiracil Mycoplasma" exact="pneumonia" post="(Sun and Wang, 2013) Valaciclovir Acyclic guanosine analogue HSV,"/>
 <result pre="in the treatment and prophylaxis of HIV, HBV and HCV" exact="infections" post="HIV, HBV and HCV are three blood-borne viruses that"/>
 <result pre="HBV and HCV are three blood-borne viruses that cause emerging" exact="infectious diseases" post="in humans worldwide (Leoni et al., 2018). According to"/>
 <result pre="humans worldwide (Leoni et al., 2018). According to the WHO," exact="viral hepatitis" post="caused 1.34 million deaths in 2015, a number that"/>
 <result pre="worldwide (Leoni et al., 2018). According to the WHO, viral" exact="hepatitis" post="caused 1.34 million deaths in 2015, a number that"/>
 <result pre="is comparable to the number of annual deaths caused by" exact="tuberculosis" post="and that is even higher than those attributed to"/>
 <result pre="is even higher than those attributed to HIV. A global" exact="hepatitis" post="report concluded that mortality from HIV, tuberculosis, and malaria"/>
 <result pre="global hepatitis report concluded that mortality from HIV, tuberculosis, and" exact="malaria" post="is now declining, while mortality from viral hepatitis has"/>
 <result pre="HIV, tuberculosis, and malaria is now declining, while mortality from" exact="viral hepatitis" post="has been increasing over time (World Health Organization, 2017)."/>
 <result pre="tuberculosis, and malaria is now declining, while mortality from viral" exact="hepatitis" post="has been increasing over time (World Health Organization, 2017)."/>
 <result pre="people, that is, 3.5% of the population, were living with" exact="chronic" post="HBV infection. Individuals in the African and Western Pacific"/>
 <result pre="population, were living with chronic HBV infection. Individuals in the" exact="African" post="and Western Pacific regions accounted for 68% of those"/>
 <result pre="These individuals are at risk of developing severe complications, including" exact="cirrhosis" post="and hepatocellular carcinoma. In 2015, hepatitis B resulted in"/>
 <result pre="are at risk of developing severe complications, including cirrhosis and" exact="hepatocellular carcinoma." post="In 2015, hepatitis B resulted in 887,000 deaths, mostly"/>
 <result pre="developing severe complications, including cirrhosis and hepatocellular carcinoma. In 2015," exact="hepatitis" post="B resulted in 887,000 deaths, mostly due to complications."/>
 <result pre="living with HIV in 2015, an estimated 2.7 million had" exact="chronic" post="HBV infection, and 2.3 million had been infected with"/>
 <result pre="and mortality among those living with HIV and coinfected with" exact="viral hepatitis." post="People with these conditions should be prioritized for diagnosis"/>
 <result pre="preventive strategies and treatment options are characterized by lifelong and" exact="chronic" post="treatment, while for HCV, short-term and curative treatment is"/>
 <result pre="not persist in cells, the elimination of HBV and HIV" exact="infections" post="worldwide is primarily hindered by their persistence in the"/>
 <result pre="Several nucleos(t)ide-based therapies are currently approved for the treatment of" exact="chronic" post="HBV infection (Liu et al., 2018). Approved nucleos(t)ide inhibitors"/>
 <result pre="therapies are currently approved for the treatment of chronic HBV" exact="infection" post="(Liu et al., 2018). Approved nucleos(t)ide inhibitors of HBV"/>
 <result pre="competes with natural nucleotide substrates for incorporation into the elongating" exact="viral" post="DNA chain. The lack of a 3′-OH group in"/>
 <result pre="linkage essential for continued DNA chain elongation, and therefore, the" exact="viral" post="DNA growth is terminated. Lamivudine (2′,3′-dideoxy-3′-thia-β-L-cytidine, 3TC) is an"/>
 <result pre="prodrugs in the treatment and prophylaxis of HIV and HBV" exact="infections" post="were comprehensively compared by De Clercq (De Clercq, 2018)."/>
 <result pre="HBV infections. Telbivudine (L-thymidine) is used in the treatment of" exact="hepatitis" post="B infection. Clinical trials have shown that this drug"/>
 <result pre="confers endothelial-protective effects on B19V-infected endothelial cells and improves the" exact="chronic" post="myocarditis associated with B19V transcriptional activity (Van Linthout et"/>
 <result pre="endothelial-protective effects on B19V-infected endothelial cells and improves the chronic" exact="myocarditis" post="associated with B19V transcriptional activity (Van Linthout et al.,"/>
 <result pre="transcriptional activity (Van Linthout et al., 2018). Treatment of HBV" exact="infections" post="is usually carried out as a monotherapy; thus, combination"/>
 <result pre="combination treatments have been the standard for the treatment of" exact="HIV infection" post="for many years. Nucleoside reverse transcriptase inhibitors (NRTIs) are"/>
 <result pre="treatments have been the standard for the treatment of HIV" exact="infection" post="for many years. Nucleoside reverse transcriptase inhibitors (NRTIs) are"/>
 <result pre="4 clinical trials for HIV-HBV coinfection (NCT03547908 and NCT03797014). The" exact="primary" post="objective of this study is to evaluate the efficacy"/>
 <result pre="was approved by the FDA in 2013 for use against" exact="chronic hepatitis" post="C infection. Sofosbuvir was the first drug that demonstrated"/>
 <result pre="approved by the FDA in 2013 for use against chronic" exact="hepatitis" post="C infection. Sofosbuvir was the first drug that demonstrated"/>
 <result pre="demonstrated safety and efficacy in treating certain types of HCV" exact="infection" post="without the need for co-administration of INF. The high"/>
 <result pre="is under phase 2 clinical trial for use in HBV" exact="infection" post="(NCT03312023). It has been observed that patients who had"/>
 <result pre="(NCT03312023). It has been observed that patients who had both" exact="hepatitis" post="B and hepatitis C and who were treated for"/>
 <result pre="been observed that patients who had both hepatitis B and" exact="hepatitis" post="C and who were treated for hepatitis C for"/>
 <result pre="hepatitis B and hepatitis C and who were treated for" exact="hepatitis" post="C for 12 weeks with a combination of ledipasvir/sofosbuvir"/>
 <result pre="for 12 weeks with a combination of ledipasvir/sofosbuvir had decreased" exact="hepatitis" post="B surface antigen levels. This finding was the basis"/>
 <result pre="a similar decrease could be observed in mono-infected individuals with" exact="hepatitis" post="B. Sofosbuvir was also recently shown to protect against"/>
 <result pre="flaviviruses, such as dengue virus (DENV) (Xu et al., 2017)," exact="yellow fever" post="virus (YFV) (De Freitas et al., 2019), and chikungunya"/>
 <result pre="yellow fever virus (YFV) (De Freitas et al., 2019), and" exact="chikungunya" post="virus (CHIKV) (Ferreira et al., 2019). 3 Multi-target nucleos(t)ide-based"/>
 <result pre="90 antiviral drugs are currently approved for the treatment of" exact="viral" post="infections, many are suitable for use only with a"/>
 <result pre="and Li, 2016). New antiviral drugs with activity against multiple" exact="viral" post="types are being sought, and many of these compounds"/>
 <result pre="is infected with HSV-1 or HSV-2. HSV is a highly" exact="infectious" post="virus that causes so-called cold sores of the mouth"/>
 <result pre="causes so-called cold sores of the mouth (in cases of" exact="infection" post="with HSV-1) or on the genitals (in cases of"/>
 <result pre="infection with HSV-1) or on the genitals (in cases of" exact="infection" post="with HSV-2). These viruses can also attack the central"/>
 <result pre="of infection with HSV-2). These viruses can also attack the" exact="central nervous system" post="and cause encephalitis. HSV-1 can be transmitted through oral"/>
 <result pre="and Hong, 2018). For VZV, which is another herpesvirus, the" exact="infection" post="occurs most often in childhood and causes chickenpox. Unfortunately,"/>
 <result pre="which is another herpesvirus, the infection occurs most often in" exact="childhood" post="and causes chickenpox. Unfortunately, even in cured patients, the"/>
 <result pre="(Littler and Zhou, 2007). Drugs used clinically for treating herpesvirus" exact="infections" post="can be divided into two categories: nucleoside analogues and"/>
 <result pre="nucleoside analogues and non-nucleoside drugs. Both types of drugs target" exact="viral" post="DNA polymerase. Nucleoside-type drugs enter cells through concentrative nucleoside"/>
 <result pre="2012). The second and third phosphorylation steps are performed by" exact="viral" post="kinases. The triphosphorylated nucleoside formed in this way is"/>
 <result pre="and it can bind to the active sites of the" exact="viral" post="DNA polymerase and act as a competitive inhibitor of"/>
 <result pre="and act as a competitive inhibitor of this enzyme during" exact="viral" post="DNA synthesis. The active form of nucleoside-type drugs can"/>
 <result pre="nucleoside-type drugs can also act as a substrate for the" exact="viral" post="enzyme and can be incorporated into the DNA chain,"/>
 <result pre="incorporated into the DNA chain, preventing the prolongation of the" exact="viral" post="DNA and possibly causing the accumulation of mutations in"/>
 <result pre="and Piérard, 1994). However, significant toxicity is associated with its" exact="systemic" post="use. The mechanism of action of idoxuridine is not"/>
 <result pre="of idoxuridine is not exactly defined, but the triphosphate inhibits" exact="viral" post="DNA synthesis and is incorporated into both viral and"/>
 <result pre="triphosphate inhibits viral DNA synthesis and is incorporated into both" exact="viral" post="and cellular DNA. Currently, in the United States, idoxuridine"/>
 <result pre="Europe, idoxuridine in DMSO is available for the treatment of" exact="herpes" post="labialis, herpes genitalis and herpes zoster (Aoki, 2015). Fig."/>
 <result pre="in DMSO is available for the treatment of herpes labialis," exact="herpes" post="genitalis and herpes zoster (Aoki, 2015). Fig. 4 Nucleoside-based"/>
 <result pre="available for the treatment of herpes labialis, herpes genitalis and" exact="herpes zoster" post="(Aoki, 2015). Fig. 4 Nucleoside-based marketed drugs against various"/>
 <result pre="for the treatment of herpes labialis, herpes genitalis and herpes" exact="zoster" post="(Aoki, 2015). Fig. 4 Nucleoside-based marketed drugs against various"/>
 <result pre="a comparison of brivudine, famciclovir and valaciclovir treatment in immunocompetent" exact="adult" post="patients with herpes zoster indicate that brivudine may be"/>
 <result pre="brivudine, famciclovir and valaciclovir treatment in immunocompetent adult patients with" exact="herpes zoster" post="indicate that brivudine may be the first choice in"/>
 <result pre="famciclovir and valaciclovir treatment in immunocompetent adult patients with herpes" exact="zoster" post="indicate that brivudine may be the first choice in"/>
 <result pre="brivudine may be the first choice in cases of severe" exact="herpes zoster" post="because of its ability to promptly control pain and"/>
 <result pre="may be the first choice in cases of severe herpes" exact="zoster" post="because of its ability to promptly control pain and"/>
 <result pre="been evaluated for their cytotoxic activity against a panel of" exact="cancer" post="cell lines. Compared to parent nucleoside, such as idoxuridine"/>
 <result pre="is used as an anti-HSV drug in therapy for HSV-induced" exact="epithelial" post="keratitis. After its conversion to trifluridine monophosphate, it inhibits"/>
 <result pre="monophosphate, it inhibits thymidylate synthetase, which is elevated in different" exact="cancer" post="cell lines. After further phosphorylation, the corresponding triphosphate competitively"/>
 <result pre="United States, and the European Union for the treatment of" exact="adult" post="patients with metastatic colorectal cancer who were previously subjected"/>
 <result pre="the European Union for the treatment of adult patients with" exact="metastatic" post="colorectal cancer who were previously subjected to chemotherapy involving"/>
 <result pre="European Union for the treatment of adult patients with metastatic" exact="colorectal cancer" post="who were previously subjected to chemotherapy involving fluoropyrimidine, oxaliplatin"/>
 <result pre="Union for the treatment of adult patients with metastatic colorectal" exact="cancer" post="who were previously subjected to chemotherapy involving fluoropyrimidine, oxaliplatin"/>
 <result pre="and efficacy of trifluridine-tipiracil during the treatment of patients with" exact="metastatic" post="colorectal cancer (NCT03306394). Trifluridine was also tested as an"/>
 <result pre="efficacy of trifluridine-tipiracil during the treatment of patients with metastatic" exact="colorectal cancer" post="(NCT03306394). Trifluridine was also tested as an antibacterial agent."/>
 <result pre="of trifluridine-tipiracil during the treatment of patients with metastatic colorectal" exact="cancer" post="(NCT03306394). Trifluridine was also tested as an antibacterial agent."/>
 <result pre="because acyclovir triphosphate is a much better substrate for the" exact="viral" post="polymerase than for the cellular polymerase. Additionally, because the"/>
 <result pre="cellular polymerase. Additionally, because the affinity of acyclovir for the" exact="viral" post="thymidine kinase is approximately 200-fold greater than that for"/>
 <result pre="2017, studies conducted to determine the effect of acyclovir on" exact="breast cancer" post="MCF-7 cells were described (Shaimerdenova et al., 2017). The obtained"/>
 <result pre="studies conducted to determine the effect of acyclovir on breast" exact="cancer" post="MCF-7 cells were described (Shaimerdenova et al., 2017). The obtained"/>
 <result pre="The obtained results demonstrate the suppressive effect of acyclovir on" exact="breast cancer" post="cells. Acyclovir treatment decreases the proliferation rate as well"/>
 <result pre="obtained results demonstrate the suppressive effect of acyclovir on breast" exact="cancer" post="cells. Acyclovir treatment decreases the proliferation rate as well"/>
 <result pre="inhibits the colony formation ability and cell invasion capacity of" exact="cancer" post="cells. These results demonstrate the possibility of partial suppression"/>
 <result pre="capacity of cancer cells. These results demonstrate the possibility of" exact="partial" post="suppression of cancer cell proliferation using this antiviral agent."/>
 <result pre="cells. These results demonstrate the possibility of partial suppression of" exact="cancer" post="cell proliferation using this antiviral agent. However, further research"/>
 <result pre="an approach based on the phosphorylation of acyclovir by the" exact="viral" post="thymidine kinase but not the cellular enzyme (Yao et"/>
 <result pre="would be a cytotoxic agent when properly delivered to the" exact="cancer" post="cells. To facilitate the targeted delivery of phosphorylated acyclovir"/>
 <result pre="has superseded acyclovir for the treatment of HSV or VZV" exact="infections" post="(O'Brien and Campoli-Richards, 1989; Littler and Zhou, 2007). Penciclovir"/>
 <result pre="its active metabolite, competitively inhibits the replicative function of the" exact="viral" post="DNA polymerase. Unlike acyclovir, penciclovir is not considered a"/>
 <result pre="its longer half-life and higher intracellular concentration compensate for the" exact="lower" post="antiviral effect. Phosphorylated penciclovir concentrations can be as much"/>
 <result pre="using other drugs is its ability to prevent latent HSV-1" exact="infections" post="(Thackray and Field, 1998). Ganciclovir (GCV, 9-[(1,3-dihydroxy-2-propoxymethyl)]guanine) differs from"/>
 <result pre="ganciclovir has been approved for use in the treatment of" exact="infections" post="with this virus, which belongs to the so-called beta-herpesvirus"/>
 <result pre="Ganciclovir has been used with some success in treating HHV-6" exact="infections" post="(Nakano et al., 2009) and has also been proven"/>
 <result pre="Streptomyces antibioticus. Vidarabine, unlike previously discussed drugs, does not require" exact="viral" post="enzymes at any step of the triphosphorylation process to"/>
 <result pre="animal models. Vidarabine triphosphate acts as a competitive inhibitor of" exact="viral" post="and cellular DNA polymerase. It functions as a chain"/>
 <result pre="incorporation into the DNA. Additionally, this metabolite also inhibits other" exact="viral" post="and cellular enzymes, such as ribonucleoside reductase and S-adenosylhomocysteine"/>
 <result pre="antiviral drug for the systematic treatment of HSV and VZV" exact="infections" post="(De Clercq, 2013b). Vidarabine is used less currently than"/>
 <result pre="adenylyl cyclase 5 for the treatment of two human diseases:" exact="heart" post="failure and cancer. This conclusion was based on the"/>
 <result pre="the preliminary stages of clinical trials for the inhibition of" exact="viral" post="DNA polymerase. This ester nucleoside analogue is rapidly converted"/>
 <result pre="converted to omaciclovir (H2G) in vivo and subsequently converted by" exact="viral" post="enzymes into the phosphorylated form that binds to VZV"/>
 <result pre="1991). Valomaciclovir was under phase 2 clinical trials for EBV-infectious" exact="mononucleosis" post="(NCT00575185) as well as for the treatment of herpes"/>
 <result pre="EBV-infectious mononucleosis (NCT00575185) as well as for the treatment of" exact="herpes zoster" post="(NCT00831103). Cyclopropavir (MBX-400) is another extensively investigated compound. It"/>
 <result pre="mononucleosis (NCT00575185) as well as for the treatment of herpes" exact="zoster" post="(NCT00831103). Cyclopropavir (MBX-400) is another extensively investigated compound. It"/>
 <result pre="a phase 2 clinical trial in comparison with valaciclovir for" exact="herpes zoster" post="(NCT00900783) and in a phase 3 clinical trial in"/>
 <result pre="phase 2 clinical trial in comparison with valaciclovir for herpes" exact="zoster" post="(NCT00900783) and in a phase 3 clinical trial in"/>
 <result pre="It was studied for safety and efficacy against adenovirus (AdV)" exact="infection" post="(phase 3 clinical trials; NCT02087306) and against serious diseases"/>
 <result pre="2) revealed that patients taking brincidofovir were resistant to CMV" exact="infection" post="(NCT942305). Unfortunately, the results of the phase 3 trial"/>
 <result pre="including leukaemias, lymphomas, and pancreatic, breast, bladder, ovarian, colon or" exact="kidney cancer." post="By mimicking the physiological role of their natural counterparts,"/>
 <result pre="synthase or ribonucleotide reductase) and thus inhibit cell division and" exact="viral" post="replication (Jordheim et al., 2013). Among the major players"/>
 <result pre="floxuridine in 1970), which have had important roles in several" exact="cancer" post="treatments (Parker, 2009). Some of the cytotoxic nucleoside analogues"/>
 <result pre="could be connected with their side effects and toxicity (e.g.," exact="myelosuppression" post="or pulmonary toxicity). However, the concentrations of nucleoside analogues"/>
 <result pre="connected with their side effects and toxicity (e.g., myelosuppression or" exact="pulmonary" post="toxicity). However, the concentrations of nucleoside analogues that inhibited"/>
 <result pre="of nucleoside analogues that inhibited the growth of bacteria were" exact="lower" post="than those used for the treatment of cancer patients,"/>
 <result pre="bacteria were lower than those used for the treatment of" exact="cancer" post="patients, which can reduce the problem of toxicity (Jordheim"/>
 <result pre="the treatment of different cancers (e.g., pancreatic, ovarian, lung and" exact="breast" post="and bladder cancer) (Hertel et al., 1990; Cerqueira et"/>
 <result pre="approved in 1998 for the treatment of locally advanced or" exact="metastatic" post="non-small cell lung cancer, and Gemzar in combination with"/>
 <result pre="for the treatment of locally advanced or metastatic non-small cell" exact="lung cancer," post="and Gemzar in combination with paclitaxel was approved as"/>
 <result pre="paclitaxel was approved as the first-line therapy for women battling" exact="metastatic" post="breast cancer. Gemzar demonstrates dose-dependent synergistic activity with cisplatin."/>
 <result pre="was approved as the first-line therapy for women battling metastatic" exact="breast cancer." post="Gemzar demonstrates dose-dependent synergistic activity with cisplatin. In the"/>
 <result pre="dose-dependent synergistic activity with cisplatin. In the treatment of advanced" exact="ovarian cancer" post="(at least 6 months after completion of platinum-based therapy),"/>
 <result pre="synergistic activity with cisplatin. In the treatment of advanced ovarian" exact="cancer" post="(at least 6 months after completion of platinum-based therapy),"/>
 <result pre="study showed that co-treatment with gemcitabine and zidovudine re-sensitized gemcitabine-resistant" exact="pancreatic cancer" post="by inhibiting the key signalling pathway, Akt-GSK3β-Snail1, in the"/>
 <result pre="showed that co-treatment with gemcitabine and zidovudine re-sensitized gemcitabine-resistant pancreatic" exact="cancer" post="by inhibiting the key signalling pathway, Akt-GSK3β-Snail1, in the"/>
 <result pre="brivudine with gemcitabine or cisplatin enhanced their efficacy as a" exact="pancreatic cancer" post="therapy (Heinrich et al., 2011). Recently (2018), the FDA"/>
 <result pre="with gemcitabine or cisplatin enhanced their efficacy as a pancreatic" exact="cancer" post="therapy (Heinrich et al., 2011). Recently (2018), the FDA"/>
 <result pre="(Rawson et al., 2013; Clouser et al., 2010, 2012), murine" exact="leukaemia" post="virus (MuLV) (Clouser et al., 2012), HIV-2 (Beach et"/>
 <result pre="the virus, gemcitabine was shown to be an inhibitor of" exact="viral" post="replication, proliferation, RNA and protein synthesis, or production. The"/>
 <result pre="two actions. It can be directly incorporated into newly synthesized" exact="viral" post="RNA during the polymerization process. Gemcitabine preferentially incorporates into"/>
 <result pre="viral RNA during the polymerization process. Gemcitabine preferentially incorporates into" exact="viral" post="RNA since the RNA replication process in viruses is"/>
 <result pre="binding to the nucleotide-binding regions. Another possibility is that the" exact="viral" post="ribonucleotide reductase is inhibited, resulting in an increased mutation"/>
 <result pre="inhibited, resulting in an increased mutation rate and loss of" exact="viral" post="proliferation capability (Kang et al., 2015). It was postulated"/>
 <result pre="the inhibition of RNA replication might be related to the" exact="limited" post="amount of nucleoside available (Song et al., 2017). As"/>
 <result pre="FDA in 2004 for the treatment of all subtypes of" exact="myelodysplastic syndrome" post="(MDS). To date, azacytidine has also been approved for"/>
 <result pre="in 2004 for the treatment of all subtypes of myelodysplastic" exact="syndrome" post="(MDS). To date, azacytidine has also been approved for"/>
 <result pre="date, azacytidine has also been approved for the treatment of" exact="acute" post="myeloid leukaemia (AML) patients with 20–30% bone marrow (BM)"/>
 <result pre="has also been approved for the treatment of acute myeloid" exact="leukaemia" post="(AML) patients with 20–30% bone marrow (BM) blasts and"/>
 <result pre="2009; Rawson et al., 2016a), HIV-2 (Beach et al., 2014)," exact="Rift Valley fever" post="virus (RVFV) (Ianevski et al., 2018, 2019), human T-lymphotropic"/>
 <result pre="in the HIV-1 mutation rate caused by incorporating azacytidine into" exact="viral" post="RNA was observed (Dapp et al., 2009). An additional"/>
 <result pre="the reduced accumulation of reverse transcription products rather than increased" exact="viral" post="mutagenesis (Rawson et al., 2016b). A recent study on"/>
 <result pre="approved by the FDA in 2006 for the treatment of" exact="multiple types" post="of myelodysplastic syndrome. It promotes cytotoxic DNA hypomethylation and"/>
 <result pre="FDA in 2006 for the treatment of multiple types of" exact="myelodysplastic syndrome." post="It promotes cytotoxic DNA hypomethylation and cell death in"/>
 <result pre="Similar to azacytidine, decitabine also induces immune responses and sensitizes" exact="tumours" post="to checkpoint inhibition (Wolff et al., 2017). Additionally, it"/>
 <result pre="et al., 2017). Additionally, it was shown that in muscle-invasive" exact="bladder cancer" post="cells, decitabine treatment (at low non-cytotoxic doses) restored NOTCH1"/>
 <result pre="al., 2017). Additionally, it was shown that in muscle-invasive bladder" exact="cancer" post="cells, decitabine treatment (at low non-cytotoxic doses) restored NOTCH1"/>
 <result pre="that the combination of gemcitabine and decitabine at concentrations much" exact="lower" post="than those used in cancer treatment synergistically lowered HIV-1"/>
 <result pre="and decitabine at concentrations much lower than those used in" exact="cancer" post="treatment synergistically lowered HIV-1 infectivity by 73% and significantly"/>
 <result pre="is an antineoplastic agent used to treat lymphoblastic leukaemia, specifically" exact="acute lymphoblastic leukaemia" post="in paediatric patients aged 1–21 whose disease has relapsed"/>
 <result pre="antineoplastic agent used to treat lymphoblastic leukaemia, specifically acute lymphoblastic" exact="leukaemia" post="in paediatric patients aged 1–21 whose disease has relapsed"/>
 <result pre="specifically acute lymphoblastic leukaemia in paediatric patients aged 1–21 whose" exact="disease" post="has relapsed or become refractory after at least two"/>
 <result pre="It limits the deoxyribonucleoside triphosphate substrates for the synthesis of" exact="viral" post="DNA and directly inhibits the DNA polymerase activity of"/>
 <result pre="90 antiviral drugs are currently approved for the treatment of" exact="viral" post="infections, many of them are suitable for use only"/>
 <result pre="a single virus. New antiviral drugs with activity against multiple" exact="viral" post="types are being sought, and many of these compounds"/>
 <result pre="data open the possibility of repurposing broad-spectrum antimetabolites to other" exact="viral" post="infections. Because these drugs have already been approved, such"/>
 <result pre="one virus may be suitable for the treatment of other" exact="viral" post="infections. This approach is particularly important for candidates for"/>
 <result pre="is particularly important for candidates for the treatment of deadly" exact="viral" post="infections, such as Ebola virus (EBOV). In this case,"/>
 <result pre="those that are currently applied for drugs used to control" exact="chronic" post="infections such as HIV and HBV. References References AbeleG.CoxS.BergmanS.LindborgB.VissgardenA.KarlstromA.HarmenbergJ.WahrenB.Antiviral"/>
 <result pre="that are currently applied for drugs used to control chronic" exact="infections" post="such as HIV and HBV. References References AbeleG.CoxS.BergmanS.LindborgB.VissgardenA.KarlstromA.HarmenbergJ.WahrenB.Antiviral activity"/>
 <result pre="and HBV. References References AbeleG.CoxS.BergmanS.LindborgB.VissgardenA.KarlstromA.HarmenbergJ.WahrenB.Antiviral activity against VZV and HSV" exact="type 1" post="and type 2 of the (+) and (-) enantiomers"/>
 <result pre="References AbeleG.CoxS.BergmanS.LindborgB.VissgardenA.KarlstromA.HarmenbergJ.WahrenB.Antiviral activity against VZV and HSV type 1 and" exact="type 2" post="of the (+) and (-) enantiomers of (R,S)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine, in"/>
 <result pre="Associations and highlight differences between antiherpesvirus drugsJ. Virol.8620122641265210.1128/jvi.06620-1122190713 AokiF.Y.Antivirals against" exact="herpes" post="virusesMandell, Douglas, and Bennett's Principles and Practice of Infectious"/>
 <result pre="against herpes virusesMandell, Douglas, and Bennett's Principles and Practice of" exact="Infectious" post="Diseaseseighth ed.2015 BauerL.LyooH.van der SchaarH.M.StratingJ.R.van KuppeveldF.J.Direct-acting antivirals and host-targeting"/>
 <result pre="to combat enterovirus infectionsCurr. Opin. Virol.2420171810.1016/j.coviro.2017.03.00928411509 BeachL.B.RawsonJ.M.KimB.PattersonS.E.ManskyL.M.Novel inhibitors of human" exact="immunodeficiency" post="virus type 2 infectivityJ. Gen. Virol.9520142778278310.1099/vir.0.069864-025103850 BeranR.K.F.SharmaR.CorsaA.C.TianY.GoldeJ.LundgaardG.Delaney IVW.E.ZhongW.GreensteinA.E.Cellular growth"/>
 <result pre="enterovirus infectionsCurr. Opin. Virol.2420171810.1016/j.coviro.2017.03.00928411509 BeachL.B.RawsonJ.M.KimB.PattersonS.E.ManskyL.M.Novel inhibitors of human immunodeficiency virus" exact="type 2" post="infectivityJ. Gen. Virol.9520142778278310.1099/vir.0.069864-025103850 BeranR.K.F.SharmaR.CorsaA.C.TianY.GoldeJ.LundgaardG.Delaney IVW.E.ZhongW.GreensteinA.E.Cellular growth kinetics distinguish a"/>
 <result pre="inhibitor from an HSP90 inhibitor as a selective inhibitor of" exact="hepatitis" post="C virusPLoS One72012e3028610.1371/journal.pone.0030286 BöslK.IanevskiA.ThanT.T.AndersenP.I.KuivanenS.TepporM.ZusinaiteE.DumpisU.VitkauskieneA.CoxR.J.Kallio-KokkoH.BergqvistA.TensonT.OksenychV.BjøråsM.AnthonsenM.W.ShumD.KaarbøM.VapalahtiO.WindischM.P.Superti-FurgaG.SnijderB.KainovD.KandasamyR.K.Critical nodes of virus-host interaction revealed"/>
 <result pre="sofosbuvir inhibits Zika virus infectionAntivir. Res.137201713414010.1016/j.antiviral.2016.11.02327902933 BurnessC.B.DugganS.T.Trifluridine/tipiracil: a review in" exact="metastatic" post="colorectal cancerDrugs7620161393140210.1007/s40265-016-0633-927568360 Cano-SoldadoP.Pastor-AngladaM.Transporters that translocate nucleosides and structural similar"/>
 <result pre="mechanism of clofarabineRetrovirology13201611210.1186/s12977-016-0254-026728316 DappM.J.ClouserC.L.PattersonS.ManskyL.M.5-Azacytidine can induce lethal mutagenesis in human" exact="immunodeficiency" post="virus type 1J. Virol.832009119501195810.1128/jvi.01406-0919726509 DasD.HongJ.Herpesvirus Polymerase Inhibitors, Viral Polymerases2018Elsevier"/>
 <result pre="clofarabineRetrovirology13201611210.1186/s12977-016-0254-026728316 DappM.J.ClouserC.L.PattersonS.ManskyL.M.5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus" exact="type 1J." post="Virol.832009119501195810.1128/jvi.01406-0919726509 DasD.HongJ.Herpesvirus Polymerase Inhibitors, Viral Polymerases2018Elsevier Inc DasP.DelostM.D.QureshiM.H.SmithD.T.NjardarsonJ.T.A survey"/>
 <result pre="in human immunodeficiency virus type 1J. Virol.832009119501195810.1128/jvi.01406-0919726509 DasD.HongJ.Herpesvirus Polymerase Inhibitors," exact="Viral" post="Polymerases2018Elsevier Inc DasP.DelostM.D.QureshiM.H.SmithD.T.NjardarsonJ.T.A survey of the structures of US"/>
 <result pre="Rev.3320131215124810.1002/med22553111 De ClercqE.Selective anti-herpesvirus agentsAntivir. Chem. Chemother.2320139310110.3851/IMP253323343513 De ClercqE.Viruses and" exact="viral" post="diseasesCompr. Med. Chem. II200725329310.1016/b0-08-045044-x/00211-x De ClercqE.Discovery and development of"/>
 <result pre="of BVDU (brivudin) as a therapeutic for the treatment of" exact="herpes" post="zosterBiochem. Pharmacol.6820042301231510.1016/j.bcp.2004.07.03915548377 De FreitasC.S.HigaL.M.SacramentoC.Q.FerreiraA.C.ReisP.A.DelvecchioR.MonteiroF.L.Barbosa-LimaG.James WestgarthH.VieiraY.R.MattosM.RochaN.HoelzL.V.B.LemeR.P.P.BastosM.M.RodriguesG.O.L.LopesC.E.M.Queiroz-JuniorC.M.LimaC.X.CostaV.V.TeixeiraM.M.BozzaF.A.BozzaP.T.BoechatN.TanuriA.SouzaT.M.L.Yellow fever virus is susceptible"/>
 <result pre="Biol. Chem.2872012353243533210.1074/jbc.M112.39214222910914 DiamantopoulosP.T.MichaelM.BenopoulouO.BazanisE.TzeletasG.MeletisJ.VayopoulosG.ViniouN.A.Antiretroviral activity of 5-azacytidine during treatment of a" exact="HTLV-1" post="positive myelodysplastic syndrome with autoimmune manifestationsVirol. J.92012110.1186/1743-422X-9-122214262 DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.JahrlingP.B.LaidlawM.JohansenL.M.Lear-RooneyC.M.GlassP.J.HensleyL.E.FriemanM.B.Repurposing of"/>
 <result pre="DiamantopoulosP.T.MichaelM.BenopoulouO.BazanisE.TzeletasG.MeletisJ.VayopoulosG.ViniouN.A.Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive" exact="myelodysplastic syndrome" post="with autoimmune manifestationsVirol. J.92012110.1186/1743-422X-9-122214262 DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.JahrlingP.B.LaidlawM.JohansenL.M.Lear-RooneyC.M.GlassP.J.HensleyL.E.FriemanM.B.Repurposing of clinically developed drugs"/>
 <result pre="activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic" exact="syndrome" post="with autoimmune manifestationsVirol. J.92012110.1186/1743-422X-9-122214262 DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.JahrlingP.B.LaidlawM.JohansenL.M.Lear-RooneyC.M.GlassP.J.HensleyL.E.FriemanM.B.Repurposing of clinically developed drugs"/>
 <result pre="5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with" exact="autoimmune" post="manifestationsVirol. J.92012110.1186/1743-422X-9-122214262 DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.JahrlingP.B.LaidlawM.JohansenL.M.Lear-RooneyC.M.GlassP.J.HensleyL.E.FriemanM.B.Repurposing of clinically developed drugs for treatment"/>
 <result pre="DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.JahrlingP.B.LaidlawM.JohansenL.M.Lear-RooneyC.M.GlassP.J.HensleyL.E.FriemanM.B.Repurposing of clinically developed drugs for treatment of Middle East" exact="respiratory" post="syndrome coronavirus infectionAntimicrob. Agents Chemother.5820144885489310.1128/aac.03036-1424841273 ElionG.B.FurmanP.A.FyfeJ.A.De MirandaP.BeauchamptL.SchaeffertH.J.Selectivity of action"/>
 <result pre="of clinically developed drugs for treatment of Middle East respiratory" exact="syndrome" post="coronavirus infectionAntimicrob. Agents Chemother.5820144885489310.1128/aac.03036-1424841273 ElionG.B.FurmanP.A.FyfeJ.A.De MirandaP.BeauchamptL.SchaeffertH.J.Selectivity of action of"/>
 <result pre="virus/virus-specified DNA polymerase/acycloguanosine triphosphate)Med. Sci.74197757165720 EssmannV.WildenhoffK.E.Antiviral treatment of VaricellaZoster and" exact="herpes" post="simplexLancet31519801337133910.1016/S0140-6736(80)91790-0 FerreiraA.C.ReisP.A.de FreitasC.S.SacramentoC.Q.HoelzL.V.B.BastosM.M.MattosM.RochaN.de Azevedo QuintanilhaI.G.da Silva Gouveia PedrosaC.SouzaL.R.Q.LoiolaE.C.TrindadeP.VieiraY.R.Barbosa-LimaG.de Castro"/>
 <result pre="Faria NetoH.C.BoechatN.RehenS.K.BrüningK.BozzaF.A.BozzaP.T.SouzaT.M.L.Beyond members of the Flaviviridae family, sofosbuvir also inhibits" exact="chikungunya" post="virus replicationAntimicrob. Agents Chemother.63201910.1128/AAC.01389-18e01389-18 FlorescuD.F.PergamS.A.NeelyM.N.QiuF.JohnstonC.WayS.S.SandeJ.LewinsohnD.A.Guzman-CottrillJ.A.GrahamM.L.PapanicolaouG.KurtzbergJ.RigdonJ.PainterW.Mommeja-MarinH.LanierR.AndersonM.van der HorstC.Safety and efficacy"/>
 <result pre="and efficacy of CMX001 as salvage therapy for severe adenovirus" exact="infections" post="in immunocompromised patientsBiol. Blood Marrow Transplant.18201273173810.1016/j.bbmt.2011.09.00721963623 GaoL.J.De JongheS.DaelemansD.HerdewijnP.L-Aspartic and"/>
 <result pre="as salvage therapy for severe adenovirus infections in immunocompromised patientsBiol." exact="Blood" post="Marrow Transplant.18201273173810.1016/j.bbmt.2011.09.00721963623 GaoL.J.De JongheS.DaelemansD.HerdewijnP.L-Aspartic and l-glutamic acid ester-based ProTides"/>
 <result pre="shock protein HSP27 (HSPB1) and enhances survival in animals and" exact="pancreatic cancer" post="patientsJ. Cancer Res. Clin. Oncol.13720111349136110.1007/s00432-011-1005-121833720 HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG. aToddG.C.GrindeyG.B.Evaluation of the"/>
 <result pre="protein HSP27 (HSPB1) and enhances survival in animals and pancreatic" exact="cancer" post="patientsJ. Cancer Res. Clin. Oncol.13720111349136110.1007/s00432-011-1005-121833720 HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG. aToddG.C.GrindeyG.B.Evaluation of the"/>
 <result pre="(HSPB1) and enhances survival in animals and pancreatic cancer patientsJ." exact="Cancer" post="Res. Clin. Oncol.13720111349136110.1007/s00432-011-1005-121833720 HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG. aToddG.C.GrindeyG.B.Evaluation of the antitumor activity"/>
 <result pre="IanevskiA.ZusinaiteE.KuivanenS.StrandM.LysvandH.TepporM.KakkolaL.PaavilainenH.LaajalaM.Kallio-KokkoH.ValkonenM.KanteleA.TellingK.LutsarI.LetjukaP.MetelitsaN.OksenychV.BjøråsM.NordbøS.A.DumpisU.VitkauskieneA.ÖhrmalmC.BondesonK.BergqvistA.AittokallioT.CoxR.J.EvanderM.HukkanenV.MarjomakiV.JulkunenI.VapalahtiO.TensonT.MeritsA.KainovD.Novel activities of safe-in-human broad-spectrum antiviral agentsAntivir. Res.154201817418210.1016/j.antiviral.2018.04.01629698664 IwatsuboK.BravoC.UechiM.BaljinnyamE.NakamuraT.UmemuraM.LaiL.GaoS.YanL.ZhaoX.ParkM.QiuH.OkumuraS.IwatsuboM.VatnerD.E.VatnerS.F.IshikawaY.Prevention of" exact="heart" post="failure in mice by an antiviral agent that inhibits"/>
 <result pre="heart failure in mice by an antiviral agent that inhibits" exact="type 5" post="cardiac adenylyl cyclaseAm. J. Physiol. Cell Physiol.3022012H2622H262810.1152/ajpheart.00190.2012 JabsD.A.WingardJ.R.de BustrosS.de"/>
 <result pre="JordheimL.P.DurantelD.ZoulimF.DumontetC.Advances in the development of nucleoside and nucleotide analogues for" exact="cancer" post="and viral diseasesNat. Rev. Drug Discov.12201344746410.1038/nrd401023722347 JulanderJ.G.SiddharthanV.EvansJ.TaylorR.TolbertK.ApuliC.StewartJ.CollinsP.GebreM.NeilsonS.Van WettereA.LeeY.M.SheridanW.P.MorreyJ.D.BabuY.S.Efficacy of"/>
 <result pre="the development of nucleoside and nucleotide analogues for cancer and" exact="viral" post="diseasesNat. Rev. Drug Discov.12201344746410.1038/nrd401023722347 JulanderJ.G.SiddharthanV.EvansJ.TaylorR.TolbertK.ApuliC.StewartJ.CollinsP.GebreM.NeilsonS.Van WettereA.LeeY.M.SheridanW.P.MorreyJ.D.BabuY.S.Efficacy of the broad-spectrum"/>
 <result pre="ribavirin against enterovirusesAntivir. Res.124201511010.1016/j.antiviral.2015.10.01126526589 KimberlinD.W.Antiviral Agents. Principles and Practice of" exact="Pediatric" post="Infectious DiseasesFifth. ed2018 KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and gemcitabine inhibit"/>
 <result pre="against enterovirusesAntivir. Res.124201511010.1016/j.antiviral.2015.10.01126526589 KimberlinD.W.Antiviral Agents. Principles and Practice of Pediatric" exact="Infectious" post="DiseasesFifth. ed2018 KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika"/>
 <result pre="Infectious DiseasesFifth. ed2018 KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika" exact="virus infection" post="in vitro and differentially affect cellular signaling, transcription and"/>
 <result pre="DiseasesFifth. ed2018 KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus" exact="infection" post="in vitro and differentially affect cellular signaling, transcription and"/>
 <result pre="differentially affect cellular signaling, transcription and metabolismAntivir. Res.139201711712810.1016/j.antiviral.2016.12.02228049006 LahmerT.HoffmannD.HeemannU.KüchleC.FrankH.Epstein-Barr virus" exact="encephalitis" post="after kidney transplantation and successful treatment with brivudineTranspl. Int.232010e24e2510.1111/j.1432-2277.2009.01045.x20070626"/>
 <result pre="and subtype profiling of PSI-7977 as a nucleotide inhibitor of" exact="hepatitis" post="C virusAntimicrob. Agents Chemother.5620123359336810.1128/aac.00054-1222430955 LaskinO.L.Acyclovir: pharmacology and clinical experienceArch."/>
 <result pre="experienceArch. Intern. Med.14419841241124610.1001/archinte.1984.003501801810256329117 LeeK.KimD.-E.JangK.-S.KimS.-J.ChoS.KimC.Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus" exact="infections" post="through innate immunity induced by the inhibition of pyrimidine"/>
 <result pre="virusAntimicrob. Agents Chemother.27198597197310.1128/AAC.27.6.9712992367 LittlerE.ZhouX.-X.Deoxyribonucleic acid viruses: antivirals for herpesviruses and" exact="hepatitis" post="B virusCompr. Med. Chem. II200729532710.1016/b0-08-045044-x/00212-1 LiuL.Z.SunJ.HouJ.ChanH.L.Y.Improvements in the management"/>
 <result pre="B virusCompr. Med. Chem. II200729532710.1016/b0-08-045044-x/00212-1 LiuL.Z.SunJ.HouJ.ChanH.L.Y.Improvements in the management of" exact="chronic hepatitis" post="B virus infectionExpert Rev. Gastroenterol.1220181153116610.1080/17474124.2018.1530986 LookerK.J.MagaretA.S.MayM.T.TurnerK.M.E.VickermanP.GottliebS.L.NewmanL.M.Global and regional estimates"/>
 <result pre="virusCompr. Med. Chem. II200729532710.1016/b0-08-045044-x/00212-1 LiuL.Z.SunJ.HouJ.ChanH.L.Y.Improvements in the management of chronic" exact="hepatitis" post="B virus infectionExpert Rev. Gastroenterol.1220181153116610.1080/17474124.2018.1530986 LookerK.J.MagaretA.S.MayM.T.TurnerK.M.E.VickermanP.GottliebS.L.NewmanL.M.Global and regional estimates"/>
 <result pre="Rev. Gastroenterol.1220181153116610.1080/17474124.2018.1530986 LookerK.J.MagaretA.S.MayM.T.TurnerK.M.E.VickermanP.GottliebS.L.NewmanL.M.Global and regional estimates of prevalent and incident" exact="herpes" post="simplex virus type 1 infections in 2012PLoS One10201511710.1371/journal.pone.0140765 LuberA.D.FlahertyJ.F.Famciclovir"/>
 <result pre="and regional estimates of prevalent and incident herpes simplex virus" exact="type 1" post="infections in 2012PLoS One10201511710.1371/journal.pone.0140765 LuberA.D.FlahertyJ.F.Famciclovir for treatment of herpesvirus"/>
 <result pre="estimates of prevalent and incident herpes simplex virus type 1" exact="infections" post="in 2012PLoS One10201511710.1371/journal.pone.0140765 LuberA.D.FlahertyJ.F.Famciclovir for treatment of herpesvirus infectionsAnn."/>
 <result pre="LuczkowiakJ.�?lvarezM.Sebastián-MartínA.Menéndez-AriasL.DNA-dependent DNA polymerases as drug targets in herpesviruses and poxviruses," exact="viral" post="polymerases2019 MatsuokaK.NakagawaF.KobunaiT.TakechiT.Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory"/>
 <result pre="of bicyclic nucleoside analogues as potent and selective inhibitors of" exact="varicella" post="zoster virusJ. Antimicrob. Chemother.6020071316133010.1093/jac/dkm37617956908 Menéndez-AriasL.�?lvarezM.PachecoB.Nucleoside/nucleotide analog inhibitors of hepatitis"/>
 <result pre="bicyclic nucleoside analogues as potent and selective inhibitors of varicella" exact="zoster" post="virusJ. Antimicrob. Chemother.6020071316133010.1093/jac/dkm37617956908 Menéndez-AriasL.�?lvarezM.PachecoB.Nucleoside/nucleotide analog inhibitors of hepatitis B"/>
 <result pre="of varicella zoster virusJ. Antimicrob. Chemother.6020071316133010.1093/jac/dkm37617956908 Menéndez-AriasL.�?lvarezM.PachecoB.Nucleoside/nucleotide analog inhibitors of" exact="hepatitis" post="B virus polymerase: mechanism of action and resistanceCurr. Opin."/>
 <result pre="liquid chromatographyJ. Virol. Methods161200922323010.1016/j.jviromet.2009.06.01619559728 NambaT.KodamaR.MoritomoS.HoshinoT.MizushimaT.Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant" exact="pancreatic cancer" post="cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathwayCell"/>
 <result pre="chromatographyJ. Virol. Methods161200922323010.1016/j.jviromet.2009.06.01619559728 NambaT.KodamaR.MoritomoS.HoshinoT.MizushimaT.Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic" exact="cancer" post="cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathwayCell"/>
 <result pre="of influenza virus by three nucleoside analogsJ. Virol.8920153584359710.1128/jvi.03483-1425589650 PiretJ.BoivinG.Resistance of" exact="herpes" post="simplex viruses to nucleoside analogues: mechanisms, prevalence, and managementAntimicrob."/>
 <result pre="of thymidineBBA - Biochim. Biophys. Acta32195929529610.1016/0006-3002(59)90597-913628760 QuenelleD.C.LampertB.CollinsD.J.RiceT.L.PainterG.R.KernE.R.Efficacy of CMX001 against" exact="herpes" post="simplex virus infections in mice and correlations with drug"/>
 <result pre="Biochim. Biophys. Acta32195929529610.1016/0006-3002(59)90597-913628760 QuenelleD.C.LampertB.CollinsD.J.RiceT.L.PainterG.R.KernE.R.Efficacy of CMX001 against herpes simplex virus" exact="infections" post="in mice and correlations with drug distribution studiesJ. Infect."/>
 <result pre="ribonucleotide reductaseBioorg. Med. Chem.2420162410242210.1016/j.bmc.2016.03.05227117260 RehermannB.BertolettiA.Immunological aspects of antiviral therapy of" exact="chronic hepatitis" post="B virus and hepatitis C virus infectionsHepatology61201571272110.1002/hep.2732325048716 SagnelliE.SagnelliC.MaceraM.PisaturoM.CoppolaN.An update"/>
 <result pre="reductaseBioorg. Med. Chem.2420162410242210.1016/j.bmc.2016.03.05227117260 RehermannB.BertolettiA.Immunological aspects of antiviral therapy of chronic" exact="hepatitis" post="B virus and hepatitis C virus infectionsHepatology61201571272110.1002/hep.2732325048716 SagnelliE.SagnelliC.MaceraM.PisaturoM.CoppolaN.An update"/>
 <result pre="aspects of antiviral therapy of chronic hepatitis B virus and" exact="hepatitis" post="C virus infectionsHepatology61201571272110.1002/hep.2732325048716 SagnelliE.SagnelliC.MaceraM.PisaturoM.CoppolaN.An update on the treatment options"/>
 <result pre="for HBV/HCV coinfectionExpert Opin. Pharmacother.1820171691170210.1080/14656566.2017.139823329081251 SandriniM.P.B.ClausenA.R.OnS.L.W.AarestrupF.M.Munch-PetersenB.PiškurJ.Nucleoside analogues are activated by" exact="bacterial" post="deoxyribonucleoside kinases in a species-specific mannerJ. Antimicrob. Chemother.60200751052010.1093/jac/dkm24017615154 SchaefferH.J.BeauchampL.de"/>
 <result pre="Antimicrob. Chemother.60200751052010.1093/jac/dkm24017615154 SchaefferH.J.BeauchampL.de MirandaP.ElionG.B.BauerD.J.CollinsP.9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the" exact="herpes" post="groupNature2721978583585205792 SeifertR.Vidarabine is neither a potent nor a selective"/>
 <result pre="the nucleoside scaffoldAntivir. Res.1542018668610.1016/j.antiviral.2018.04.00429649496 ShaimerdenovaM.KarapinaO.MektepbayevaD.AlibekK.AkilbekovaD.The effects of antiviral treatment on" exact="breast cancer" post="cell lineInfect. Agents Cancer12201711010.1186/s13027-017-0128-728053656 ShinH.J.KimC.ChoS.Gemcitabine and nucleos(t)ide synthesis inhibitors"/>
 <result pre="nucleoside scaffoldAntivir. Res.1542018668610.1016/j.antiviral.2018.04.00429649496 ShaimerdenovaM.KarapinaO.MektepbayevaD.AlibekK.AkilbekovaD.The effects of antiviral treatment on breast" exact="cancer" post="cell lineInfect. Agents Cancer12201711010.1186/s13027-017-0128-728053656 ShinH.J.KimC.ChoS.Gemcitabine and nucleos(t)ide synthesis inhibitors"/>
 <result pre="luoro-2′-β- C -methyluridine Nucleotide Prodrug (PSI-7977) for the treatment of" exact="hepatitis" post="C virusJ. Med. Chem.5320107202721810.1021/jm100863x20845908 SongJ.H.KimS.R.HeoE.Y.LeeJ.Y.KimD. eunChoS.ChangS.Y.YoonB. IlSeongJ.KoH.J.Antiviral activity of"/>
 <result pre="analogsBMC Microbiol.13201318410.1186/1471-2180-13-18423919755 ThackrayA.M.FieldH.J.Famciclovir and valaciclovir differ in the prevention of" exact="herpes" post="simplex virus type 1 latency in mice: a quantitative"/>
 <result pre="and valaciclovir differ in the prevention of herpes simplex virus" exact="type 1" post="latency in mice: a quantitative studyAntimicrob. Agents Chemother.4219981555156210.1128/AAC.42.7.15559660982 TheobaldR.J.Vidarabine."/>
 <result pre="herpesviruses DNA polymeraseNucleic Acids Res.4420169530955410.1093/nar/gkw87527694307 TyringS.BarbarashR.A.NahlikJ.E.CunninghamA.MarleyJ.HengM.JonesT.ReaT.BoonR.SaltzmanR.BruceS.HarrisA.EpsteinA.LowryL.RubinH.DupuyJ.HendricksJ.GreerJ.RapaportM.Famciclovir for the treatment of" exact="acute" post="herpes zoster: effects on acute disease and postherpetic neuralgia."/>
 <result pre="DNA polymeraseNucleic Acids Res.4420169530955410.1093/nar/gkw87527694307 TyringS.BarbarashR.A.NahlikJ.E.CunninghamA.MarleyJ.HengM.JonesT.ReaT.BoonR.SaltzmanR.BruceS.HarrisA.EpsteinA.LowryL.RubinH.DupuyJ.HendricksJ.GreerJ.RapaportM.Famciclovir for the treatment of acute" exact="herpes" post="zoster: effects on acute disease and postherpetic neuralgia. A"/>
 <result pre="TyringS.BarbarashR.A.NahlikJ.E.CunninghamA.MarleyJ.HengM.JonesT.ReaT.BoonR.SaltzmanR.BruceS.HarrisA.EpsteinA.LowryL.RubinH.DupuyJ.HendricksJ.GreerJ.RapaportM.Famciclovir for the treatment of acute herpes zoster: effects on" exact="acute" post="disease and postherpetic neuralgia. A randomized, double-blind, placebo- controlled"/>
 <result pre="for the treatment of acute herpes zoster: effects on acute" exact="disease" post="and postherpetic neuralgia. A randomized, double-blind, placebo- controlled trialAnn."/>
 <result pre="treatment of acute herpes zoster: effects on acute disease and" exact="postherpetic neuralgia." post="A randomized, double-blind, placebo- controlled trialAnn. Intern. Med.1231995899610.7326/0003-4819-123-2-199507150-000027778840 Van"/>
 <result pre="randomized, double-blind, placebo- controlled trialAnn. Intern. Med.1231995899610.7326/0003-4819-123-2-199507150-000027778840 Van LinthoutS.ElsanhouryA.KleinO.SosnowskiM.MitevaK.LassnerD.Abou-El-EneinM.PieskeB.KühlU.TschöpeC.Telbivudine in" exact="chronic" post="lymphocytic myocarditis and human parvovirus B19 transcriptional activityESC Hear."/>
 <result pre="placebo- controlled trialAnn. Intern. Med.1231995899610.7326/0003-4819-123-2-199507150-000027778840 Van LinthoutS.ElsanhouryA.KleinO.SosnowskiM.MitevaK.LassnerD.Abou-El-EneinM.PieskeB.KühlU.TschöpeC.Telbivudine in chronic lymphocytic" exact="myocarditis" post="and human parvovirus B19 transcriptional activityESC Hear. Fail.5201881882910.1002/ehf2.12341 VatnerS.F.ParkM.YanL.LeeG.J.LaiL.IwatsuboK.IshikawaY.PessinJ.VatnerD.E.Adenylyl"/>
 <result pre="and human parvovirus B19 transcriptional activityESC Hear. Fail.5201881882910.1002/ehf2.12341 VatnerS.F.ParkM.YanL.LeeG.J.LaiL.IwatsuboK.IshikawaY.PessinJ.VatnerD.E.Adenylyl cyclase" exact="type 5" post="in cardiac disease, metabolism, and agingAm. J. Physiol. Cell"/>
 <result pre="B19 transcriptional activityESC Hear. Fail.5201881882910.1002/ehf2.12341 VatnerS.F.ParkM.YanL.LeeG.J.LaiL.IwatsuboK.IshikawaY.PessinJ.VatnerD.E.Adenylyl cyclase type 5 in" exact="cardiac disease," post="metabolism, and agingAm. J. Physiol. Cell Physiol.3052013H1H810.1152/ajpheart.00080.2013 WellerS.BlumM.R.DoucetteM.BurnetteT.CederbergD.M.MirandaP. DeSmileyM.L.Pharmacolunetics"/>
 <result pre="and multiple-dose adrninis tration normal volunteersClin. Pharmacol. Ther.19935956058275615 WestoverJ.B.MathisA.TaylorR.WanderseeL.BaileyK.W.SefingE.J.HickersonB.T.JungK.H.SheridanW.P.GowenB.B.Galidesivir limits" exact="Rift Valley fever" post="virus infection and disease in Syrian golden hamstersAntivir. Res.1562018384510.1016/j.antiviral.2018.05.01329864447"/>
 <result pre="tration normal volunteersClin. Pharmacol. Ther.19935956058275615 WestoverJ.B.MathisA.TaylorR.WanderseeL.BaileyK.W.SefingE.J.HickersonB.T.JungK.H.SheridanW.P.GowenB.B.Galidesivir limits Rift Valley fever" exact="virus infection" post="and disease in Syrian golden hamstersAntivir. Res.1562018384510.1016/j.antiviral.2018.05.01329864447 WolffF.LeischM.GreilR.RischA.PleyerL.The double-edged"/>
 <result pre="normal volunteersClin. Pharmacol. Ther.19935956058275615 WestoverJ.B.MathisA.TaylorR.WanderseeL.BaileyK.W.SefingE.J.HickersonB.T.JungK.H.SheridanW.P.GowenB.B.Galidesivir limits Rift Valley fever virus" exact="infection" post="and disease in Syrian golden hamstersAntivir. Res.1562018384510.1016/j.antiviral.2018.05.01329864447 WolffF.LeischM.GreilR.RischA.PleyerL.The double-edged"/>
 <result pre="Pharmacol. Ther.19935956058275615 WestoverJ.B.MathisA.TaylorR.WanderseeL.BaileyK.W.SefingE.J.HickersonB.T.JungK.H.SheridanW.P.GowenB.B.Galidesivir limits Rift Valley fever virus infection and" exact="disease" post="in Syrian golden hamstersAntivir. Res.1562018384510.1016/j.antiviral.2018.05.01329864447 WolffF.LeischM.GreilR.RischA.PleyerL.The double-edged sword of"/>
 <result pre="double-edged sword of (re)expression of genes by hypomethylating agents: from" exact="viral" post="mimicry to exploitation as priming agents for targeted immune"/>
 <result pre="for targeted immune checkpoint modulationCell Commun. Signal.15201711410.1186/s12964-017-0168-z28073373 World Health OrganizationGlobal" exact="Hepatitis" post="Report, 20172017World Health Organisation XuH.T.Colby-GerminarioS.P.HassounahS.A.FogartyC.OsmanN.PalanisamyN.HanY.OliveiraM.QuanY.WainbergM.A.Evaluation of Sofosbuvir (β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine) as"/>
 <result pre="Health Organisation XuH.T.Colby-GerminarioS.P.HassounahS.A.FogartyC.OsmanN.PalanisamyN.HanY.OliveiraM.QuanY.WainbergM.A.Evaluation of Sofosbuvir (β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine) as an inhibitor of" exact="Dengue" post="virus replicationSci. Rep.7201711110.1038/s41598-017-06612-228127051 YaldizM.SolakB.KaraR.O.CosansuN.ErdemM.T.Comparison of famciclovir, valaciclovir, and brivudine"/>
 <result pre="replicationSci. Rep.7201711110.1038/s41598-017-06612-228127051 YaldizM.SolakB.KaraR.O.CosansuN.ErdemM.T.Comparison of famciclovir, valaciclovir, and brivudine treatments in" exact="adult" post="immunocompetent patients with herpes zosterAm. J. Therapeut.920161910.1097/MJT.0000000000000436 YaoJ.ZhangY.RamishettiS.WangY.HuangL.Turning an"/>
 <result pre="famciclovir, valaciclovir, and brivudine treatments in adult immunocompetent patients with" exact="herpes" post="zosterAm. J. Therapeut.920161910.1097/MJT.0000000000000436 YaoJ.ZhangY.RamishettiS.WangY.HuangL.Turning an antiviral into an anticancer"/>
</results>
